RCRobert Kay Cooper

Robert Kay Cooper

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Robert Kay Cooper has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Working Alliance and Subjective Engagement with a Digital Avatar CBT Platform (RITch®CBT): Comparing Young Adults with and Without Co-Occurring Substance Use and Depression

    by Victoria Pezzino, Cassandra Berbary, Courtney McKinney, Celeste Sangiorgio, Emi Moriuchi, Korena S. Klimczak, Robert Kay Cooper, Wonkyung Kniffen, Maya Hareli, Cory Crane, et al.

    Digital mental health interventions (DMHIs) can help bridge treatment gaps experienced by young adults with co-occurring substance misuse and depression. However, it remains unclear whether engagement with these interventions differs for young adults with co-occurring conditions compared to those experiencing substance misuse or depression alone. To investigate this issue, we assessed working alliance and subjective engagement with a digital avatar-assisted cognitive-behavioral therapy (CBT) treatment platform (RITch®CBT), comparing young adults with substance use, depression, and the co-occurrence of the two. A secondary data analysis was conducted on a sample of 99 young adults aged 18–28 years who presented at an urban university clinic. Participants rated their alliance and engagement following two brief sessions of the RITch®CBT platform. Participants were then categorized into behavioral health groups. Repeated exposure to the program had a greater impact on subjective engagement and usability across diagnostic conditions, but there was no difference in working alliance reported across sessions or behavioral health groups. Further, participants’ depressive symptoms were significantly correlated with the number of sessions they expressed they were willing to engage in and attend. Our findings suggest that digital tools may support early engagement in treatment for young adults, regardless of presenting problem.

  • Do lab-based assessments of pretreatment smoking reinforcement and cue-specific craving predict smoking cessation with varenicline?

    by Robert K. Cooper, Julie Gass, Martin C. Mahoney, Stephen T. Tiffany, Craig R. Colder, Eugene Maguin, Nicolas J. Schlienz, Schuyler C. Lawson, Rachel F. Tyndale, Baltaj Sandhur, et al.

    Individual differences in smoking reinforcement and cue-specific cigarette craving are theorized to influence smoking cessation and relapse. However, there has been little laboratory research that prospectively evaluates these relationships. The present study evaluated whether lab-based indices of pretreatment smoking reinforcement and cue-specific craving predicted subsequent bio-verified abstinence. Participants were 253 adults (aged 28-70, 54% female, 78% White, 3% Hispanic) who reported smoking more than five cigarettes per day when enrolled in a randomized, double-blind, placebo-controlled smoking cessation trial (NCT03262662). During a lab visit ∼1 week before treatment began, participants completed the Choice Behavior under Cued Conditions task. On each of the 36 Choice Behavior under Cued Conditions trials, participants spent between $0.01 and $0.25 for a chance (5%-95%) to sample a cigarette or a cup of water. All participants received varenicline, either during Weeks 1-15 or 4-15 of the study, along with counseling at each visit, and attempted to quit smoking at the end of Week 4. Cotinine-bio-verified (< 15 ng/mL) 7-day point-prevalence abstinence was assessed at Weeks 6, 8, 15, and 28. The predictive validity of pretreatment smoking reinforcement and cue-specific craving on abstinence were examined in logistic regressions. As predicted, greater pretreatment smoking reinforcement predicted lower odds of abstinence, an effect that did not vary significantly across time, treatment groups, or biological sex. Pretreatment cue-specific craving was not predictive of abstinence. This study highlights the theoretical importance of smoking reinforcement and the predictive utility of Choice Behavior under Cued Conditions in identifying those at risk for relapse. (PsycInfo Database Record (c) 2025 APA, all rights reserved).

  • Open Access

    Sex-Specific Mediation of Pre-Quit Smoking Reduction: Secondary Analysis of a Randomized Controlled Trial Extending Varenicline Preloading

    by Samantha Johnstone, Robert K Cooper, Jennifer M Wray, Sarah Tonkin, Kyler S Knapp, Craig R Colder, Eugene Maguin, Martin C Mahoney, Stephen T Tiffany, Thomas H Brandon, et al.

    Introduction: Relative to other pharmacotherapies for smoking cessation, varenicline has significantly greater efficacy in females; however, sex-specific mechanisms have not yet been investigated. We conducted a secondary analysis of ecological momentary assessment data to assess whether reductions in craving, negative affect, and smoking satisfaction/reward/aversion mediate effects of varenicline on next-day smoking to a greater degree in females (n = 179) relative to males (n = 141). Aims and Methods: Data were from a 3-week medication manipulation period during the pre-quit phase of a double-blind randomized placebo-controlled trial investigating extended preloading (4 weeks) versus standard preloading of varenicline (1 week, preceded by 3 weeks of placebo, NCT03262662). Time-invariant multi-level moderated mediation models and time-varying mediation models were utilized. Results: A significant time-varying indirect effect through craving that increased in magnitude over the pre-quit period was identified only in females. Exploratory analysis found that decreases in psychological reward and smoking satisfaction mediated the relationship between varenicline and reductions in craving only in females. Time-invariant multi-level models did not evidence a significant indirect effect through candidate mediators in males or females; the index of moderated mediation was not significant in any of the models. Conclusions: Our findings suggest that the efficacy of varenicline on reductions in pre-quit smoking in females operates through reductions in craving. Furthermore, reductions in craving may be due to decreases in positive subjective experiences of smoking. Augmenting craving coping strategies as well as reducing smoking reward and satisfaction may be a beneficial approach in females. Implications: This is the first study to investigate sex-specific mediation of varenicline on reductions in pre-quit smoking. Further investigation into varenicline-induced changes in smoking reinforcement and craving is warranted, particularly in females. For example, experimentally manipulating these mediators may inform them as mechanisms for smoking reduction.


  • Relationships Between the Nicotine Metabolite Ratio and Laboratory Assessments of Smoking Reinforcement and Craving Among Adults in a Smoking Cessation Trial

    by Robert K Cooper, Martin C Mahoney, Stephen T Tiffany, Craig R Colder, Rachel F Tyndale, Larry W Hawk

    Introduction: People who metabolize nicotine more quickly are generally less successful at quitting smoking. However, the mechanisms that link individual differences in the nicotine metabolite ratio (NMR), a phenotypic biomarker of the rate of nicotine clearance, to smoking outcomes are unclear. We tested the hypotheses that higher NMR is associated with greater smoking reinforcement, general craving, and cue-induced cigarette craving in a treatment-seeking sample. Methods: Participants were 252 adults who smoke cigarettes enrolled in a randomized controlled smoking cessation trial (NCT03262662) conducted in Buffalo, New York, USA. Participants completed the Choice Behavior Under Cued Conditions (CBUCC) paradigm, a laboratory choice procedure, ~1 week before the first cessation treatment visit, at which time a saliva sample was collected for NMR assessment. On each CBUCC trial, participants reported cigarette craving during cue presentation (cigarette, water) and spent $0.01–$0.25 for a chance (5%–95%) to sample the cue (one puff, sip), providing measures of smoking reinforcement (spending for cigarettes vs. water), general cigarette craving (averaged across cigarette and water cues), and cue-specific craving (cigarette craving during cigarette vs. water cues). Results: As observed in prior work, the NMR was significantly higher among White and female participants. As expected, both spending and cigarette craving were significantly greater on cigarette compared to water trials. However, contrary to our hypotheses, higher NMR was not associated with greater smoking reinforcement, general craving, or cue-specific craving. Conclusions: The present data do not support that smoking reinforcement or craving is related to nicotine metabolism among individuals seeking to quit smoking. Implications: Though greater smoking reinforcement, general craving, and cue-specific craving are hypothesized to be linked to faster nicotine metabolism, there was no evidence of such relationships in the present sample of adults seeking to quit smoking. Further research, including replication and consideration of alternate hypotheses, is warranted to elucidate the mechanisms by which the NMR is related to smoking cessation.


  • Caffeine enhances sustained attention among adolescents.

    by Robert K. Cooper, Schuyler C. Lawson, Sarah S. Tonkin, Amanda M. Ziegler, Jennifer L. Temple, Larry W. Hawk

    Despite the growing interest in caffeine use and its effects among adolescents, and a large literature on caffeine and attention among adults, there is a lack of experimental work examining the impact of caffeine on sustained attention among adolescents. We evaluated the acute effects of caffeine (vs. placebo) during a long (33-min) classic vigilance task among 31 adolescents (aged 12-17; 15 female; median caffeine use = 28 mg/day). We predicted a dose-dependent effect of caffeine, which would attenuate declines in target detection over time (i.e., a vigilance decrement). In each of 3 visits, participants completed an identical pairs continuous performance task beginning ∼25 min after consumption of noncaloric flavored water containing placebo, 1 mg/kg, or 3 mg/kg caffeine (order counterbalanced). Percent hits for low probability targets across 12 100-trial blocks was the primary outcome measure. As predicted, the linear decline in hits across trial blocks was attenuated by caffeine (Caffeine vs. Placebo × Block Linear, p = .01), with significant improvements in Blocks 9-12 (ps < .03). Compared to 1 mg/kg, 3 mg/kg caffeine resulted in earlier improvement in target detection (Drug Dose × Block Quadratic, p = .001). This study demonstrated that caffeine acutely and dose-dependently improves sustained attention among adolescents. These results were likely due to the attention-enhancing effect of caffeine, rather than withdrawal reversal, as our sample was characterized by light to moderate caffeine use. This study provides the foundation for further work on the impact of chronic caffeine consumption on cognitive function during adolescence. (PsycInfo Database Record (c) 2021 APA, all rights reserved).